In Mark Dawson's laboratory, researchers aim to develop a molecular understanding of the role that epigenetic regulators play in the initiation and maintenance of cancer and uncover the epigenetic mechanisms by which malignancies evade therapeutic pressure. Our priority is to translate these discoveries into personalised approaches that advance clinical care.
In Sarah-Jane's Dawson's laboratory, researchers aim to develop personalised biomarkers and treatment approaches to improve outcomes for patients with cancer. Our research interests lie in understanding the evolution of cancer and using this information to develop molecular biomarkers for clinical application, including early detection, risk stratification and disease monitoring.
The major focus of our research is the development of blood-based biomarkers to enable personalised disease monitoring and facilitate therapeutic decisions in both solid and haematological malignancies.
researchers aim to develop a molecular understanding of the role that epigenetic regulators play in the initiation and maintenance of cancer and uncover the epigenetic mechanisms by which malignancies evade therapeutic pressure. Our priority is to translate these discoveries into personalised approaches that advance clinical care.
researchers aim to develop personalised biomarkers and treatment approaches to improve outcomes for patients with cancer. Our research interests lie in understanding the evolution of cancer and using this information to develop molecular biomarkers for clinical application, including early detection, risk stratification and disease monitoring.
The major focus of our research is the development of blood-based biomarkers to enable personalised disease monitoring and facilitate therapeutic decisions in both solid and haematological malignancies.
